A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma

Affiliations

• ¹ Washington University School of Medicine, Division of Oncology, St. Louis, MO. tfehnige@wustl.edu.
• ² Washington University School of Medicine, Division of Oncology, St. Louis, MO.
• ³ Washington University School of Medicine, Division of Biostatistics, St. Louis, MO.
• ⁴ Wake Forest University School of Medicine, Section of Hematology and Oncology, Winston-Salem, NC.
• ⁵ Emory University School of Medicine, Atlanta, GA.
• ⁶ Hackensack University Medical Center, Division of Lymphoma, Hackensack, NJ.
• ⁷ Medical College of Wisconsin, Hematology and Oncology, Milwaukee, WI.
• ⁸ Washington University, Mallinckrodt Institute of Radiology, Alvin J. Siteman Cancer Center, St. Louis, MO.
• ⁹ Washington University School of Medicine, Division of Oncology, St. Louis, MO. nbarlet@wuslt.edu.